Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Bavarian Nordic is now catching up to Valneva, whose Ixchiq vaccine became the world’s first licensed chikungunya vaccine when it was approved by the US Food and Drug Administration (FDA ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

In May last year, the EMA recommended granting a marketing authorization in the EU for Ixchiq, the first vaccine in the EU to protect adults 18 years and older against chikungunya. Dr Rob Hicks is ...

SC Weaver is an inventor on a UTMB patent application describing IRES-attenuated alphavirus vaccines ... in the production of this manuscript. Chikungunya virus (CHIKV) causes an acute febrile ...

Credit: Soumyabrata Roy via Getty Images. Bavarian Nordic’s chikungunya vaccine Vimkunya is one step closer to being available in Europe after having secured an European Medicines Agency (EMA) ...

When you need a break from the hustle and bustle of Canada's biggest city, you can hop on a quick, 15-minute ferry ride to the Toronto Islands. Amidst the towering skyscrapers of the city's ...